These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36894639)

  • 1. Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.
    Wu Y; Zhou L; Zou Y; Zhang Y; Zhang M; Xu L; Zheng L; He W; Yu K; Li T; Zhang X; Chen Z; Zhang R; Zhou P; Zhang N; Zheng L; Kang T
    Nat Cancer; 2023 Mar; 4(3):382-400. PubMed ID: 36894639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1/SOX10 regulatory axis.
    Martinkova L; Zatloukalova P; Kucerikova M; Friedlova N; Tylichova Z; Zavadil-Kokas F; Hupp TR; Coates PJ; Vojtesek B
    Cell Mol Biol Lett; 2024 Sep; 29(1):117. PubMed ID: 39237877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.
    Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
    Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
    Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
    Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
    Yoshino H; Sato Y; Nakano M
    Curr Issues Mol Biol; 2021 May; 43(1):153-162. PubMed ID: 34069326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.
    Gao K; Shi Q; Gu Y; Yang W; He Y; Lv Z; Ding Y; Cao W; Wang C; Wan X
    Cell Death Differ; 2023 Feb; 30(2):475-487. PubMed ID: 36481790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell.
    Shao L; Hou W; Scharping NE; Vendetti FP; Srivastava R; Roy CN; Menk AV; Wang Y; Chauvin JM; Karukonda P; Thorne SH; Hornung V; Zarour HM; Bakkenist CJ; Delgoffe GM; Sarkar SN
    Cancer Immunol Res; 2019 Aug; 7(8):1258-1266. PubMed ID: 31239318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.
    Xie Y; Ding J; Gao J; Zhang J; Cen S; Zhou J
    Int Immunopharmacol; 2023 May; 118():109993. PubMed ID: 36931170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity.
    Purbey PK; Seo J; Paul MK; Iwamoto KS; Daly AE; Feng AC; Champhekar AS; Langerman J; Campbell KM; Schaue D; McBride WH; Dubinett SM; Ribas A; Smale ST; Scumpia PO
    Cell Rep; 2024 Jun; 43(6):114289. PubMed ID: 38833371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.
    Ebine K; Kumar K; Pham TN; Shields MA; Collier KA; Shang M; DeCant BT; Urrutia R; Hwang RF; Grimaldo S; Principe DR; Grippo PJ; Bentrem DJ; Munshi HG
    Sci Rep; 2018 Sep; 8(1):13225. PubMed ID: 30185888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of STXBP6-IRF1 positive feedback loop in regulation of PD-L1 in cancer.
    Liu Y; Huang Z; Wei Y; Zhang M; Li X; Yang S; Wang H
    Cancer Immunol Immunother; 2021 Feb; 70(2):275-287. PubMed ID: 32700091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling.
    Chen Q; Zhuang S; Hong Y; Yang L; Guo P; Mo P; Peng K; Li W; Xiao N; Yu C
    Oncogene; 2022 Mar; 41(10):1421-1433. PubMed ID: 35027670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
    Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
    J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
    Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
    Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
    Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
    Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
    [No Abstract]   [Full Text] [Related]  

  • 17. Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy.
    Liang J; Wang L; Wang C; Shen J; Su B; Marisetty AL; Fang D; Kassab C; Jeong KJ; Zhao W; Lu Y; Jain AK; Zhou Z; Liang H; Sun SC; Lu C; Xu ZX; Yu Q; Shao S; Chen X; Gao M; Claret FX; Ding Z; Chen J; Chen P; Barton MC; Peng G; Mills GB; Heimberger AB
    Cancer Immunol Res; 2020 Jul; 8(7):952-965. PubMed ID: 32265228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody.
    Li R; Zhan Y; Ding X; Cui J; Han Y; Zhang J; Zhang J; Li W; Wang L; Jiang J
    Int J Biol Sci; 2024; 20(1):61-77. PubMed ID: 38164171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of programmed death-ligand 1 expression in primary normal human dermal fibroblasts after DNA damage.
    Hagiwara Y; Sato H; Permata TBM; Niimi A; Yamauchi M; Oike T; Nakano T; Shibata A
    Hum Immunol; 2018 Aug; 79(8):627-631. PubMed ID: 29859207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.
    Zhou Y; Liang Z; Xia Y; Li S; Liang J; Hu Z; Tang C; Zhao Q; Gong Q; Ouyang Y
    Chem Biol Interact; 2023 Jan; 369():110260. PubMed ID: 36414028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.